Zentalis Pharmaceuticals, Inc. (ZNTL) Posts Interim OS Benefit in Cyclin E1+ PROC

Zentalis reported interim DENALI Part 1b data: median OS 15.9 months in Cyclin E1-positive vs 7.5 months in Cyclin E1-negative PROC, with updated ORR/DOR and a safety profile consistent with prior reports.Material DetailsContext by AI AnalystThis is mid-stage confirmation of Zentalis’s biomarker-dr…